Skip to main content

Lymphoma & Myeloma

Protocols

Chronic Lymphocytic Lymphoma

LYACAL

Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib


LYALEM

Treatment with Subcutaneous or Intravenous Alemtuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alemtuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)


LYCHLOR

(See under Non-Hodgkin Lymphoma)


LYCLLBEND

Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) with Bendamustine


LYCLLBENDR

Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and riTUXimab


LYCLLCHLR

Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and riTUXimab


LYCLLCVPR

Treatment of relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab (CVP-R)


LYCLLFBR

Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and riTUXimab


LYCLLFLUDR

Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and riTUXimab


LYCLLZANU

Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib


LYCYCLO

(See under Non-Hodgkin Lymphoma)


LYFACAL

Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib


LYFCR

Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and riTUXimab


LYFIBRU

Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using iBRUtinib

LYFLU

(See under Non-Hodgkin Lymphoma)


LYIBRU

Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Ibrutinib


LYIDELAR

Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Using Idelalisib and riTUXimab


LYOBCHLOR

Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with oBINutuzumab and Chlorambucil


LYRITZ

(See under Non-Hodgkin Lymphoma)


ULYVENETO

Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax


LYVENOB

Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and oBINutuzumab

Top

Hodgkin Lymphoma

LYABVD

Treatment of Hodgkin's disease with DOXOrubicin, Bleomycin, vinBLAStine and Dacarbazine


ULYAJBV (replaced by LYBV)

Treatment for Adjuvant Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma Using Brentuximab Vedotin


LYAVDBV

Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with DOXOrubicin, vinBLAStine, Dacarbazine and Brentuximab Vedotin


 

LYBRENTUX

Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin


LYBV

Consolidation Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma Using Brentuximab Vedotin


LYCVPPABO

Treatment of Hodgkin's Disease with Cyclophosphamide, vinBLAStine, Procarbazine and predniSONE


LYCYCLO

(See under Non-Hodgkin Lymphoma)


LYGVLD

Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and DOXOrubicin Pegylated Liposomal


LYNIV

Treatment of Relapsed or Refractory Hodgkin Lymphoma Using Nivolumab Protocol


LYNIV4

Treatment of Relapsed or Refractory Hodgkin Lymphoma Using 4-Weekly Nivolumab


LYPEM

Treatment of Relapsed or Refractory Hodgkin Lymphoma using Pembrolizumab


LYPEM6

Treatment of Relapsed or Refractory Hodgkin Lymphoma Using 6-Weekly Pembrolizumab

Non-Hodgkin Lymphoma (excluding CLL)

LYBEND

Treatment of Non-Hodgkin Lymphoma with Bendamustine


LYBENDR

Treatment of Non-Hodgkin Lymphoma with Bendamustine and riTUXimab


LYCHLOR

Therapy for Low Grade Lymphoma and Chronic Lymphocytic Leukemia Using Chlorambucil


LYCHLRR

Treatment of Indolent B-cell Lymphoma with Chlorambucil and riTUXimab

LYCHOP

Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine and predniSONE


LYCHOPR

Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab


LYCHOPRMTX

Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and RiTUXimab in Diffuse Large B-cell Lymphoma


LYCODOXMR

Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRIStine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and riTUXimab


LYCVP

Treatment of Advanced indolent lymphoma using Cyclophosphamide, vinCRIStine and predniSONE


LYCVPR

Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab (CVP-R)


LYCYCLO

Therapy of Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia or Multiple Myeloma Using Cyclophosphamide


LYDHAPR

Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab


LYEPOCHR

Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, vinCRIStine, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate


LYFLU

Treatment of Low-Grade Lymphoma or Chronic Lymphocytic Leukemia with Fludarabine


LYFLUDR

Treatment of Relapsed Indolent Lymphoma with Fludarabine and riTUXimab


LYGDP

Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum


LYGDPR

Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with riTUXimab

LYHDMRP

(See LYHDMRTEM protocol)


LYHDMRTEM

Treatment of Primary and Secondary CNS Lymphoma with High Dose Methotrexate, riTUXimab and temozolomide


LYHDMTXP (deleted 01 Sep 2021)


LYHDMTXPRO

Central Nervous System Prophylaxis with High Dose Methotrexate in Diffuse Large B-Cell Lymphoma


LYHDMTXR (deleted 01 Sep 2021)


LYIT

Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine


LYIVACR

Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab


LYMIBRU

Treatment of Relapsed/Refractory Mantle-Cell Lymphoma Using iBRUtinib


LYOBBEND

Treatment of riTUXimab-refractory Follicular Lymphoma (FL) with oBINutuzumab in combination with Bendamustine


LYPOLABR

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and riTUXimab


LYRICE

Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin’s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab


LYRITUX

Treatment of Lymphoma with single agent riTUXimab


LYRITZ

Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for Ibritumomab 90Y (ZEVALIN®)


LYRMTN

Maintenance riTUXimab for Indolent Lymphoma


ULYWMZANU

Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib


ULYZANU (see ULYWMZANU)

Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib

Natural Killer or T-Cell Lymphoma

LYALIT

Treatment of Cutaneous T-cell Lymphoma (Mycosis Fungoides/Sézary Syndrome) with Alitretinoin


LYASPMEDEX

Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma Using Pegaspargase, Methotrexate and Dexamethasone


LYCARTOP

Summary for Topical Carmustine in Cutaneous T-cell Lymphoma


LYCHPBV

Treatment of CD30-Positive Peripheral T-Cell Lymphoma (PTCL) with DOXOrubicin, Cyclophosphamide, predniSONE (CHP) and Brentuximab Vedotin


LYCTCLBV

Treatment of Cutaneous T-Cell Lymphoma (CTCL) with Brentuximab Vedotin


LYGEMOXPEG

Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase


LYMECHLOR

Topical Chlormethine in Cutaneous T-cell Lymphoma


LYMFBEX

Treatment of Cutaneous T-cell Lymphoma (Mycosis Fungoides/Sézary syndrome) with Bexarotene


LYMFECP

Treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis


LYPRA

Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) with Pralatrexate


ULYROMI

Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with romiDEPsin


LYSMILE

Treatment of Natural Killer or T-Cell Lymphoma Using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide


LYVIPDRT

Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide, CISplatin and Dexamethasone

Top

Amyloidosis

Refer to Myeloma section for other protocols.

LYDARCBDF

Treatment of Previously Untreated Light Chain Amyloidosis and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone

Top

Others

HLHETCSPA

Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE


LYCDA

Treatment of Hairy Cell Leukemia with Cladribine


LYCSPA

Cyclosporine for cytopenias associated with lymphoproliferative disorder of large granular lymphocytes


LYPALL

Lymphoma Palliative Chemotherapy


LYSILTUX

Treatment of Multicentric Castleman’s Disease (MCD) Negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus – 8 (HHV-8) Using Siltuximab

Myeloma

MYBLDF

Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Bortezomib, Lenalidomide and Dexamethasone


MYBLDPRE

Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant


MYBORMTN

Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality


MYBORPRE

Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant


MYBORREL

Treatment of Relapsed Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide


MYBSD

Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide


MYCARDEX

Therapy of Multiple Myeloma Using Carfilzomib and Dexamethasone With or Without Cyclophosphamide


MYCARLD

Therapy of Multiple Myeloma Using Carfilzomib, Lenalidomide with Dexamethasone


MYDARBD

Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone With or Without Cyclophosphamide


MYDARCBDF

Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone


MYDARLD

Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone With or Without Cyclophosphamide


MYDARLDF

Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone


MYHDC

Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant


UMYISACARD

Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide


UMYISAPOMD

Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide


UMYLDF

Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone


MYLDREL

Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone


MYLENMTN

Maintenance Therapy of Multiple Myeloma Using Lenalidomide


MYMP

Treatment of Multiple Myeloma Using Melphalan and predniSONE


MYMPBOR

Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan


MYPAM

Treatment of Multiple Myeloma with Pamidronate


UMYPOMDEX

Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone


MYZOL

Treatment of Multiple Myeloma with Zoledronic Acid


Funding Algorithm

The funding algorithm provides information on what anti-cancer systemic therapy treatments are covered on the BC Cancer Benefit Drug List (formulary). It may not be a complete list of all treatment options that may be available and recommended by the treating physician.

Terms of use

The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's Terms of Use.

Tab Heading
SOURCE: Lymphoma & Myeloma ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2024 Provincial Health Services Authority